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Recent studies have uncovered thousands of long
non-coding RNAs (lncRNAs) in human pancreatic
b cells. b cell lncRNAs are often cell type specific
and exhibit dynamic regulation during differentiation
or upon changing glucose concentrations. Although
these features hint at a role of lncRNAs in b cell
gene regulation and diabetes, the function of b cell
lncRNAs remains largely unknown. In this study, we
investigated the function of b cell-specific lncRNAs
and transcription factors using transcript knock-
downs and co-expression network analysis. This
revealed lncRNAs that function in concert with tran-
scription factors to regulate b cell-specific transcrip-
tional networks. We further demonstrate that the
lncRNA PLUTO affects local 3D chromatin structure
and transcription ofPDX1, encoding a key b cell tran-
scription factor, and that both PLUTO and PDX1 are
downregulated in islets from donors with type 2 dia-
betes or impaired glucose tolerance. These results
implicate lncRNAs in the regulation of b cell-specific
transcription factor networks.
INTRODUCTION
Transcriptome surveys have uncovered tens of thousands of
mammalian transcripts longer than 200 nucleotides that have
low protein-coding potential (Carninci et al., 2005; Derrien400 Cell Metabolism 25, 400–411, February 7, 2017 ª 2016 The Auth
This is an open access article under the CC BY license (http://creativeet al., 2012; Guttman et al., 2009). A small fraction of these
long non-coding RNAs (lncRNAs) have been shown to control
gene expression by modulating chromosomal structure, tran-
scription, splicing, mRNA transport, stability, or translation (Car-
rieri et al., 2012; Chen and Carmichael, 2009; Gong and Maquat,
2011; Lai et al., 2013; Luco and Misteli, 2011; Willingham et al.,
2005; Yao et al., 2010). Specific lncRNAs have thus been impli-
cated in various key processes, including random X chromo-
some inactivation, imprinting, the cell cycle, organogenesis,
differentiation, pluripotency, and cancer progression (Guttman
et al., 2011; Huarte et al., 2010; Hung et al., 2011; Klattenhoff
et al., 2013; Kretz et al., 2013; Penny et al., 1996; Schmitt and
Chang, 2013; Sleutels et al., 2002; Ulitsky et al., 2011). Despite
these wide-ranging biological roles, the fraction of lncRNAs
that is genuinely functional and the true impact of lncRNAs in hu-
man biology and disease remain poorly understood.
Pancreatic b cells regulate glucose homeostasis by secreting
insulin and play a central role in the pathogenesis of major forms
of diabetes mellitus. Recently, more than 1,100 lncRNAs were
identified in human pancreatic islets and purified b cells (Mora´n
et al., 2012) as well as in mouse pancreatic islet cells (Benner
et al., 2014; Ku et al., 2012; Mora´n et al., 2012). A large fraction
of human b cell lncRNAs are cell-specific, and several are known
to be activated during b cell differentiation (Mora´n et al., 2012).
This cellular specificity has also been noted for lncRNAs in other
cell types (Cabili et al., 2011; Derrien et al., 2012) and points to
the possibility that lncRNAs may regulate genetic programs
important for lineage-specific differentiation or specialized
cellular functions. Further, several b cell lncRNAs were shown
to be regulated by extracellular glucose concentrations, sug-
gesting a potential role of lncRNAs in the functional adaptation
of b cells to increased insulin secretory demands (Mora´n et al.,ors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
2012). Some islet lncRNAs map to loci that contain polygenic or
Mendelian defects associated with human diabetes, whereas
selected lncRNAs show deregulation in islets from organ donors
with human type 2 diabetes (T2D) (Fadista et al., 2014; Mora´n
et al., 2012). Collectively, these properties define a newly identi-
fied class of candidate regulators of b cell differentiation and
function, with potential implications for human diabetes mellitus.
However, the true relevance of b cell lncRNAs depends on
whether they elicit a physiological function in human b cells,
which remains to be addressed systematically.
In the current study, we have focused on a set of lncRNAs that
show restricted expression in human pancreatic b cells and have
tested the hypothesis that they regulate b cell gene expression.
Our studies have uncovered a regulatory network in which line-
age-specific lncRNAs and transcription factors (TFs) control
common genes. Furthermore, we show that lncRNAs frequently
regulate genes associated with clusters of islet enhancers,
which have previously been shown to be the primary functional
targets of islet-specific TFs. We performed a detailed analysis
of a specific lncRNA named PLUTO, which controls PDX1, a
master regulator of pancreas development and b cell differenti-
ation and, thereby, modulates the PDX1-dependent transcrip-
tional program. Finally, we show that PLUTO and PDX1 are
downregulated in islets from organ donors with type 2 diabetes
or impaired glucose tolerance, suggesting a potential role in hu-
man diabetes.
RESULTS
Human b Cell lncRNA Knockdowns Cause Profound
Transcriptional Phenotypes
To directly test the regulatory function of pancreatic b cell
lncRNAs, we carried out loss-of-function experiments in a
glucose-responsive human islet b cell line, EndoC-bH1 (Ravas-
sard et al., 2011). We chose a human model because only
some human lncRNAs are evolutionary conserved (Derrien
et al., 2012; Mora´n et al., 2012; Okazaki et al., 2002; Pang
et al., 2006), and we perturbed the function of lncRNAs through
RNAi-based transcript knockdowns rather than genomic dele-
tions because deletions could potentially disrupt cis-regulatory
elements. We thus designed lentiviral vectors that contain
RNA polymerase II-transcribed artificial microRNAs (hereafter
referred to as amiRNA) with perfect homology to the target
sequence to elicit target cleavage. The amiRNAs contain an arti-
ficial stem sequence targeting our lncRNA of choice as well as
flanking and loop sequences from an endogenous miRNA to
allow their processing as pre-miRNA by the RNAi pathway (Fig-
ure S1A). As a reference, we used the same strategy to knock
down TFs that are well known to regulate gene expression in
pancreatic islets as well as five different non-targeting amiRNA
sequences as controls.
The lncRNAs selected for knockdown were derived from a
short list of 25 lncRNAs that showed (1) a markedly enriched
expression in human islets and fluorescence-activated cell sort-
ing (FACS)-purified b cells relative to the exocrine pancreas and
a panel of non-pancreatic tissues, (2) expression in the EndoC-
bH1 b cell line, and (3) a chromatin profile in human islets that
was consistent with an active promoter (Figures S1C and
S1D). Of these 25 lncRNAs, 12 were shortlisted because theywere near a protein-coding gene that has an important function
in b cells. The lncRNAs had variable subcellular enrichment pat-
terns (Figure S1B), and eight of the 12 lncRNAs had detectable
transcripts in orthologous or syntenic mouse regions (Table S1;
Mora´n et al., 2012). We then screened four amiRNA sequences
for each of the 12 lncRNAs and identified two efficient (>50%
knockdown) amiRNAs for seven lncRNAs and one efficient
amiRNA sequence for the other five lncRNAs (Figure S1E). Two
efficient amiRNAs were also obtained for five essential islet
TFs (HNF1A, GLIS3,MAFB, NKX2.2, and PDX1).We thus trans-
duced EndoC-bH1 cells with lentiviruses expressing each
amiRNA. This was done in duplicate or in triplicate for lncRNAs
that only had one efficient amiRNA. 80 hr post-transduction,
RNA was harvested and hybridized to oligonucleotide microar-
rays (Figure 1A). For each target gene, we combined expression
data from all knockdowns and compared them to the control
transductions with five different control amiRNAs to identify
genes that were differentially expressed at a significance level
of p < 103 (ANOVA) (Figure 1B).
As expected, knockdown of islet TFs consistently produced
transcriptional phenotypes (Figure 1B). Remarkably, knockdown
of 9 of the 12 islet lncRNAs also caused transcriptional changes
(Figure 1B; Figure S1F). A more detailed analysis showed that
some of the lncRNAs that presented knockdown phenotypes
had visible effects on a neighboring gene, suggesting a possible
cis-regulatory mechanism, although other such lncRNAs did not
appear to affect neighboring genes and may thus function
through trans-regulatory mechanisms (Figure 1E; Figure S1G).
These loss-of-function experiments with selected lncRNAs
therefore suggested that lncRNAs can regulate the expression
of pancreatic b cell genes.
Gene silencing using the RNAi pathway can theoretically lead
to nonspecific gene deregulation. In our experimental model, a
significant nonspecific result would occur when two unrelated
amiRNAs elicited changes in a common set of genes that were
not observed in the panel of control non-targeting amiRNAs.
To assess the likelihood that two unrelated amiRNA sequences
elicit such an effect, we studied the five sets of control (non-tar-
geting) amiRNAs, compared all ten possible combinations of two
versus three control amiRNAs, and determined the number of
differentially expressed genes (Figure 1C). Likewise, for each
TF or lncRNA that had two valid amiRNAs, we compared the
two target-specific amiRNAs against all possible combinations
of three control amiRNAs (Figure 1C). As seen in Figure 1D, con-
trol versus control comparisons generated amedian of 16 (IQR =
15–22) differentially expressed genes, whereas all five TFs and
six of the seven lncRNA knockdowns led to a significantly higher
number of differentially expressed genes (Mann-Whitney test,
p < 104 for all lncRNA/TF versus control comparisons except
HI-LNC75, p = 0.004, and HI-LNC76, p > 0.5). These results
show that the observed phenotypes are unlikely to be caused
by unspecific effects of amiRNAs and indicate that the
sequence-specific inhibition of selected islet lncRNAs can result
in transcriptional changes comparable in magnitude to the inhi-
bition of well-established islet transcriptional regulators.
The primary function of b cells is to synthesize and secrete
insulin in response to changes in glucose concentrations.
Among the genes that showed functional dependence on
lncRNAs, we identified numerous genes that are known toCell Metabolism 25, 400–411, February 7, 2017 401
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Figure 1. Knockdown of Selected b Cell lncRNAs Leads to Transcriptional Phenotypes
(A) Schematic of the experimental plan. Lentivirally encoded amiRNAs were validated and transduced in duplicate (32) or triplicate (33) into ENDOC-bH1 cells as
indicated and then analyzed with oligonucleotide expression arrays.
(B) Differential gene expression analysis revealed genes that show significant up- or downregulation after knockdown of TFs or lncRNAs. For each TF or lncRNA,
we combined all replicates transduced with the different target-specific amiRNAs and compared these with all replicates from five non-targeting controls.
Differential expression was determined at p < 103 (ANOVA).
(C) We compared gene expression data from all ten possible combinations of three versus two control non-targeting amiRNAs. Similarly, the two independent
amiRNAs that target each TF or lncRNA were compared with all ten possible combinations of three control amiRNAs. For this analysis, we only considered the
seven lncRNAs that were targeted by two independent amiRNAs.
(D) Control comparisons result in a low number of differentially regulated genes (average 15 genes), whereas most TF and lncRNA comparisons yield higher
numbers of differentially regulated genes. ***p < 104; **p < 0.01; ns, not significant compared with control comparisons; Mann-Whitney test.
(E) HI-LNC15 regulates its neighboring gene, NKX2.2, whereas HI-LNC12 knockdown (KD) does not affect its adjacent active gene, UNC5A (left). Further ex-
amples are shown in Figure S1G. RNAs were normalized to TBPmRNA and expressed relative to control amiRNAs; n = 3, error bars represent SEM; **p < 0.01,
*p < 0.05 (Student’s t test).regulate transcription or secretion in b cells, including RFX6,
PDX1, CACNA1D, ATP2A3, ROBO1 and 2, PDE8A, ATP6AP1,
KCNJ15, TRPM3, ERO1LB, and HADH (Figure 2A; Anderson
et al., 2011; Li et al., 2010; Louagie et al., 2008; Okamoto
et al., 2012; Smith et al., 2010; Tian et al., 2012; Varadi and Rut-
ter, 2002;Wagner et al., 2008; Yang et al., 2013; Zito et al., 2010).402 Cell Metabolism 25, 400–411, February 7, 2017We therefore measured insulin content and glucose-stimulated
insulin secretion (GSIS) in T antigen-excised EndoC-bH3 cells
after knocking down four lncRNAs that showed the strongest
transcriptional phenotypes (HI-LNC12, HI-LNC78, HI-LNC80,
andHI-LNC71). Congruent with the broad transcriptional pheno-
type, we observed reduced insulin content and, consequently,
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Figure 2. Knockdown of lncRNAs Impairs
Insulin Secretion
(A) Examples of genes known to play a role in b cell
function regulated by islet lncRNAs.
(B) Glucose-stimulated insulin secretion was
tested on T antigen-excised EndoC-bH3 cells after
transduction with amiRNAs targeting the indicated
lncRNAs or controls. Secreted or total insulin
content was normalized to the number of cells per
well and expressed as fold change over control
amiRNA treatment at 2.8 mM glucose. Each bar
represents an average from two independent
amiRNA vectors and 12 separate wells from two
independent experiments. Error bars represent
SEM; ***p < 103, **p < 0.01, *p < 0.05 (Student’s
t test).impaired glucose-stimulated insulin secretion for HI-LNC12, HI-
LNC78, and HI-LNC71 knockdowns (Figure 2B). For HI-LNC78,
a glucose-regulated islet transcript (Mora´n et al., 2012) that is or-
thologous to mouse Tunar and zebrafish megamind (linc-birc6)
lncRNAs (Ulitsky et al., 2011), there was a reduction in GSIS after
correcting for the reduction in insulin content (p = 0.002) (Fig-
ure S2A). To further validate these effects, the same lncRNAs
were downregulated using antisense locked nucleic acid (LNA
GapmeRs, Exiqon) GapmeRs, which also led to impaired insulin
secretion after knockdown of HI-LNC12 and HI-LNC78 (Fig-
ure S2B). Taken together, lncRNA knockdown studies identified
lncRNAs that modulate gene expression and, consequently, in-
sulin secretion in a human b cell line.
Human Islet lncRNAs and TFs Regulate Common Gene
Expression Programs
To gain insight into the expression programs that are regulated
by islet-specific lncRNAs and TFs, we compared their knock-
down gene expression phenotypes. We first assessed changes
in gene expression occurring after knockdown of the different
islet TFs and found high Pearson correlation values for all pair-
wise comparisons (r = 0.4–0.8, p < 1027) (Figure 3A; Figure S3).
This finding is consistent with the notion that islet-specific TFs
often bind to common genomic targets and function in a combi-
natorial manner (Pasquali et al., 2014; Qiu et al., 2002; Wilson
et al., 2003). Interestingly, the transcriptional changes that
occurred after the inhibition of several lncRNAs significantlyCell Metacorrelated with those observed following
inhibition of TFs (Figure 3A; Figure S3;
see also a cluster analysis of TF- and
lncRNA-dependent changes in Figure 3B).
Some pairwise comparisons that illustrate
this finding include HI-LNC78-dependent
gene expression changes, which corre-
lated highly with HNF1A- and MAFB-
dependent changes (Pearson’s r = 0.87
and 0.89, respectively, p < 1071), and
HI-LNC15-dependent changes, which
correlated with those occurring after
knockdown of NKX2-2 (r = 0.67, p =
1032) (Figure 3C). The results from these
gene knockdown experiments thereforeindicate that selected islet-specific lncRNAs and TFs can regu-
late common gene expression programs.
Islet TFs and lncRNAs Co-regulate Genes Associated
with Enhancer Clusters
Recent studies have revealed that islet TFs regulate cell-specific
transcription by targeting clusters of enhancers and, in partic-
ular, clusters with enhancers that are bound by multiple islet
TFs (Pasquali et al., 2014). Enhancer clusters share many fea-
tures with regulatory domains that have otherwise been defined
as ‘‘stretch enhancers’’ or ‘‘superenhancers’’ (Pasquali et al.,
2014; Pott and Lieb, 2015). Given that knockdown of islet
lncRNAs and TFs suggested that they regulate similar genes,
we asked whether islet lncRNAs also regulate enhancer clus-
ter-associated genes. As expected, gene set enrichment anal-
ysis (GSEA) showed that genes with islet-enriched expression,
genes associated with enhancer clusters, or genes associated
with enhancers that are bound by multiple TFs were downregu-
lated after knockdown of all five TFs, whereas this was not
observed for ten control sets of genes expressed at similar levels
(Figure 4; Figures S4A and S4B). Likewise, genes associated
with enhancer clusters and those showing islet-specific expres-
sion were also enriched among genes that were downregulated
after knockdown of HI-LNC12, 15, 30, 78, 80, 85, and 71 (Fig-
ure 4; Figures S4A and S4B). These results therefore indicate
that islet-specific TFs and lncRNAs often co-regulate genes
that are associated with enhancer clusters.bolism 25, 400–411, February 7, 2017 403
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Figure 3. Human Islet TFs and lncRNAs
Regulate Common Genes
(A) Heatmap displaying Pearson r values for all
pairwise comparisons of fold changes in gene
expression after knockdown of TFs and lncRNAs.
Only genes significantly dysregulated at p < 103
under at least one condition were included in the
analysis.
(B) Unsupervised clustering analysis of fold change
values after knockdown of five TFs and the five
lncRNAs that displayed the strongest transcrip-
tional changes. Only genes that were dysregulated
at p <103 in at least one knockdown were
selected. Blue represents downregulated and red
represents upregulated genes. Controls represent
control comparisons as described for Figure 1.
(C) Examples of highly correlated transcriptional
phenotypes. The plots show fold change values
(Log2) after knockdown of the indicated pairs of
genes. Only the top 100 most regulated genes for
any of the two knockdowns were plotted. Pear-
son’s correlation (r) and p values are displayed.b Cell lncRNAs and TFs Form Part of Islet-Specific
Co-expression Networks
We next used an independent experimental approach to validate
the observation that human b cell lncRNAs and TFs regulate
common gene expression programs. This involved the analysis
of gene modules that show co-expression across a panel of hu-
man islet RNA samples. Analogous approaches have been em-
ployed to reveal sets of genes that share functional relationships
(Derry et al., 2010; Kim et al., 2001; Pandey et al., 2010; Segal
et al., 2003; Stuart et al., 2003; Su et al., 2011). We implemented
this analysis using weighted gene co-expression analysis
(WGCNA) of RNA sequencing (RNA-seq) profiles from 64 human
pancreatic islet samples. This identified 25 major gene modules
containing more than 100 genes, named M1–M25, that showed
highly significant co-expression across human islet samples
(Figure 5A; Table S2). We next determined which co-expression
modules contained islet lncRNAs. Rather than using our previ-
ously defined set of lncRNAs, this analysis was performed with
a set of 2,373 b cell lncRNAs that was newly annotated using
5 billion stranded RNA-seq reads pooled from 41 islet samples
(Table S3; Figure S5A). bCell lncRNAswere found to be enriched
in seven pancreatic islet co-expression modules (M3, M7, M12,
M13, M18, M20, and M21) (Figure 5B).
We next characterized the nature of these seven lncRNA-en-
riched co-expression modules. Five of these (M3, M7, M12,
M18, and M20) were enriched in genes associated with pancre-404 Cell Metabolism 25, 400–411, February 7, 2017atic islet enhancer clusters (Figures 5A–
5C, marked in blue). Two other modules
(M13 and M21) were enriched for
ubiquitously expressed genes involved in
mRNA translationandmetabolic pathways
(FigureS5B). Among themodules enriched
in lncRNAs and enhancer clusters, three
(M3, M7, and M18) were also enriched in
islet-specific TF genes (Figure 5D), and
two of these modules (M3 and M7) con-
tained nine of the 12 lncRNAs that hadbeen knocked down in EndoC-bH1 cells. Module M3, the largest
of the seven lncRNA-enriched modules, featured gene ontology
(GO) terms associated with prototypical islet cell functions and
contained several islet TFs and lncRNAs (Figure 5E). In keeping
with these findings, we found numerous instances of islet
lncRNAs and known cell-specific TFs that showed a tight correla-
tion of gene expression levels across human islet samples (Fig-
ure 5F; Figure S5C). These findings thus indicated that b cell-spe-
cific lncRNAs, TFs, and genes associated with islet enhancer
clusters form part of common expression programs.
Further analysis is consistent with the notion that lncRNAs play
a functional role in driving gene expression variation in the
lncRNA-enriched co-expression modules. First, the subset of
lncRNAs that were shown to regulate an adjacent gene in knock-
down studies also exhibited a particular high co-regulation with
the adjacent gene across islet samples (Figure S1G). This obser-
vation was extended to define 292 lncRNAs that displayed a
highly significant (p < 107) correlation of expression with an
adjacent protein-coding gene in the panel of human islet sam-
ples and are thus candidate cis-regulatory lncRNAs (Table S6).
Second, we analyzed all genes that were significantly downregu-
lated in EndoC-bH1 cells after knocking downHI-LNC12, 71, 78,
and 80 and found that they were also enriched among genes in
human islet modules M3, M7, and M18 but not in size-controlled
modules (Figure S5D). In summary, co-expression analysis of
native human islets corroborated the findings observed with
p<0.05 
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Figure 4. LncRNAs Regulate Enhancer
Cluster Genes
GSEA showed that genes that were down-
regulated upon knockdown of either islet TFs or
lncRNAs were enriched in a set of 694 genes that
is associated with human islet enhancer clusters
(red dots) but not in ten control gene sets (black
dots) that were expressed at similar levels as
enhancer cluster genes.amiRNA-based perturbations in EndoC-bH1 cells and indicated
that a group of islet lncRNAs and TFs form part of common tran-
scriptional networks that target clusters of pancreatic islet en-
hancers (Figure 5G).
Deregulation of b Cell lncRNAs in Human T2D
The identification of functional lncRNAs led us to explore
whether some lncRNAs are abnormally expressed in human
T2D and might thus be relevant to the pathogenesis of this dis-
ease. We therefore analyzed our new set of 2,373 lncRNAs in a
recently reported gene expression dataset that includes human
islet samples from donors diagnosed with T2D or impaired
glucose tolerance (IGT) (Fadista et al., 2014). Our results showed
that, despite the fact that gene expression across human islet
donors is highly variable, the expression of 15 and 100 lncRNAs
was significantly altered in islets from T2D and IGT versus non-
diabetic donors respectively (adjusted p < 0.05) (Figure S6A;
see Table S7 for a complete list). This finding suggests a poten-
tial role of functional b cell lncRNAs in driving some of the b cell
gene expression changes that are associated with T2D.
PLUTO Regulates PDX1, an Essential Transcriptional
Regulator
To explore how b cell lncRNAs can regulate cell-specific tran-
scriptional networks, we focused on HI-LNC71, a nuclearly en-
riched transcript (Figure S1B) that is transcribed from a promoter
that is located 3 kb upstream of PDX1, in an antisense orienta-
tion (Figure S6B). PDX1 is an essential transcriptional regulator
of pancreas development and b cell function that has been impli-
cated in genetic mechanisms underlying Mendelian and type 2
diabetes (Ahlgren et al., 1998; Jonsson et al., 1994; Offield et al.,
1996;Stoffers et al., 1997). Basedon this genomic location,we re-
named HI-LNC71 PLUTO, for PDX1 locus upstream transcript.
The potential importance of PLUTO was strengthened by the
observation that PLUTOwas among the most markedly downre-
gulated lncRNAs in islets from T2D or IGT donors (adjusted p
value = 0.07 and 0.005, respectively; Figure 6A; Figure S6B).
Interestingly, PDX1was also downregulated in islets fromdonors
with T2D and IGT (Figure 6A).
PLUTO is a multi-isoform transcript that contains five major
exons that span nearly 100 kb, encompassing a cluster of en-
hancers that make 3D contacts with the PDX1 promoter in hu-
man islets and in EndoC-bH1 cells (Figure 6B; Figure S6A).Cell MetaThis observation suggested that PLUTO
could affect cis regulation of the PDX1
gene.
To test whether PLUTO regulates
PDX1, we first examined EndoC-bH1cells after amiRNA-mediated knockdown of PLUTO RNA and
found reduced PDX1mRNA and protein levels (Figure 6C). Simi-
larly, knockdown of PLUTO RNA in dispersed primary human
islet cells caused decreased PDX1 mRNA (Figure 6D). To vali-
date these experiments through a complementary approach,
we used CRISPR interference (CRISPRi), which involves target-
ing guide RNAs (gRNAs) downstream of a gene’s transcriptional
initiation site to block its transcription. Two independent gRNAs
that targeted a region downstream of the PLUTO initiation site
efficiently reduced PLUTO RNA levels relative to non-targeting
gRNAs, and, in both cases, this led to decreased PDX1 mRNA
expression (Figure 6E). Therefore, perturbing either PLUTO
RNA levels or its transcription leads to the same inhibitory effect
on PDX1 mRNA.
The mouse Pdx1 locus also has an islet lncRNA (Pluto) that
shows only limited sequence homology with human PLUTO.
Pluto is also transcribed from the opposite strand of Pdx1 but
is initiated from a promoter within the first intron of Pdx1 and,
like PLUTO, spans a broad regulatory domain upstream of
Pdx1 (Figure S6C). Knockdown of Pluto RNA in the mouse
b cell line MIN6 also led to decreased Pdx1 mRNA levels (Fig-
ure S6E). These experiments therefore indicated that PLUTO
regulates PDX1 mRNA in human b cell lines and primary islet
cells, and an analogous effect was observed for the mouse
lncRNA ortholog.
Consistent with this regulatory relationship, PLUTO and PDX1
RNA levels are highly correlated across islet samples (Pearson’s
r = 0.86, p = 1015; Figure 6F), and knockdown of PDX1 and
PLUTO in EndoC-bH1 cells resulted in the deregulation of a
shared set of genes (Figures 6G–6J). Furthermore, Pluto and
Pdx1 were found to be regulated with nearly identical dynamics
in response to a shift in glucose concentration (4–11 mM) in
mouse pancreatic islets (Figure S6D). PLUTO and PDX1 there-
fore regulate a common program in pancreatic islets, and
this is at least in part explained by the fact that PLUTO
regulates PDX1.
PLUTO Regulates PDX1 Transcription and Local 3D
Chromatin Structure
To assess the mechanisms underlying the function of PLUTO,
we first examined whether PLUTO controls the stability or tran-
scription of PDX1. Transcriptional inhibition experiments using
Actinomycin D showed no significant differences in the stabilitybolism 25, 400–411, February 7, 2017 405
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Figure 5. Islet-Specific Coding and Noncoding
RNAs Form Shared Co-expression Modules
(A) Topological overlap matrix representing co-
expression modules that were co-regulated across
64 human islet samples. Modules that were enriched
in lncRNAs are marked with squares (hypergeometric
test, p < 102).
(B–D)Co-expressionmodules that showedenrichment in
islet lncRNAs (B), islet enhancer cluster (EC)-associated
genes (C), or a set of 94 islet-enriched TF genes (D). Five
modules (M3, M7, M12, M18, and M20, marked in blue)
out of seven modules that were enriched in lncRNAs
were also enriched in ECs and TFs.
(E) Module M3 was enriched in typical islet-specific
biological process annotations. Right: examples of
islet TFs and lncRNAs in module M3.
(F) Correlation of the indicated lncRNAs and b cell-
specific TF mRNAs across 64 islet samples. GAPDH
is shown as a non-b cell reference. Pearson’s corre-
lation values are displayed in the top left corner. The
axes show expression values normalized across 64
islet samples.
(G) Network diagram illustrating that TFs and
lncRNAs often co-regulate the same genes, many of
which are associated with enhancer clusters.of PDX1 mRNA upon PLUTO knockdown (Figure 7A). By
contrast, intronic PDX1 RNA was reduced upon PLUTO knock-
down, suggesting that PLUTO regulates PDX1 transcription
(Figure 7B).
Because PLUTO spans an enhancer cluster, we hypothesized
that it could regulate the chromatin state of active enhancers.We
thus knocked down PLUTO in b cells andmeasured H3K27 acet-
ylation as well as H3K4 mono- and tri-methylation levels at
several enhancers within the cluster. Our results indicate no sig-
nificant changes in these characteristic active chromatin marks
(Figure S7).
We next determined whether PLUTO affects the 3D contacts
between the enhancer cluster and the PDX1 promoter. Examina-
tion of the PDX1 locus using quantitative chromatin conforma-
tion capture (3C) assays revealed that two far upstream
enhancers (Figure 7C) showed reduced contacts with the
PDX1 promoter after PLUTO knockdown (Figure 7D). These406 Cell Metabolism 25, 400–411, February 7, 2017findings therefore show that PLUTO regu-
lates the transcription of PDX1, a key
pancreatic b cell transcriptional regulator,
and that this is associated with its
ability to promote contacts between the
PDX1 promoter and its enhancer cluster
(Figure 7E).
DISCUSSION
In the current study, we have tested the
hypothesis that lncRNAs play a role in
cell-specific gene regulation in pancreatic
b cells, a cell type that is central in the path-
ogenesis of human diabetes. We have
thus carried out, for the first time, a system-
atic analysis of the function of a set ofhuman b cell-specific lncRNAs. Our experiments revealed
several examples of b cell lncRNAs in which sequence-specific
perturbation causes transcriptional and functional phenotypes.
We have further shown that b cell-specific lncRNAs and TFs
regulate a common transcriptional network. Finally, we have
demonstrated that b cell-specific lncRNAs directly or indirectly
participate in the regulation of human enhancer clusters, which
are the major functional targets of islet-specific transcription
factors and key cis-regulatory determinants of islet cell tran-
scriptional programs (Pasquali et al., 2014). Importantly, these
conclusions are supported by concordant results from co-
expression network analysis and loss of function experiments.
These studies should be interpreted in light of previous evi-
dence indicating that a significant fraction of lncRNAs show
lineage-specific expression (Cabili et al., 2011; Derrien et al.,
2012; Goff et al., 2015; Guttman et al., 2011; Iyer et al., 2015;
Mora´n et al., 2012; Pauli et al., 2012). Our study extends
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Figure 6. PLUTO Knockdown Decreases
PDX1 mRNA
(A) Downregulation of PLUTO (HI-LNC71) and
PDX1 in islets from donors with T2D or IGT. Dif-
ferential expression analysis was performed on
control (n = 50) versus T2D (n = 10) or IGT (n = 15)
samples. Boxplots represent expression normal-
ized to the mean of control samples. Adjusted
p values are shown.
(B) Schematic of the human PDX1 locus and its
associated enhancer cluster. A 4C-seq analysis
was designed to identify regions interacting with
the PDX1 promoter region in EndoC-bH1 cells.
Red and orange vertical lines depict active and
poised islet enhancers, respectively. F and R
represent forward and reverse RNA-seq strands,
respectively, and scales represent RPM. PLUTO
(HI-LNC71) was generated from a de novo as-
sembly of islet RNA-seq and differs from a tran-
script annotated in UCSC and RefSeq that origi-
nates from a PDX1 intronic region.
(C) Downregulation of PLUTO or PDX1 using
amiRNAs resulted in reduced PDX1 mRNA and
protein levels. EndoC-bH1 cells were transduced
with control (black), PLUTO (white), or PDX1 (tur-
quoise) amiRNA vectors 80 hr prior to harvest.
RNA levels were assessed by qPCR, normalized to
TBP, and expressed as fold over control amiRNA
samples (n = 4). For protein quantification, PDX1
levels were first normalized to the average of TBP
and H3 levels and then compared with the control
amiRNA sample.
(D) Downregulation of PLUTO in human islet cells
results in reduced PDX1 mRNA levels. Islet cells
were dispersed and transduced with amiRNA
vectors (n = 3) as in (B).
(E) Downregulation of PLUTO in EndoC-bH3 cells
using CRISPRi also decreases PDX1 mRNA. En-
doC-bH3 cells were nucleofected with CRISPRi
vectors 80 hr prior to harvest. RNA levels were
assessed by qPCR and normalized to TBP and
then to a control CRISPRi sample (n = 3).
(F) PDX1 and PLUTO RNA levels were highly
correlated in 64 human islet samples.
(G) Knockdown of PDX1 and PLUTO resulted in
differential expression of similar genes. Fold
change value (Log2) of top 250 dysregulated
genes following the PDX1 knockdown was plotted
against the same genes following the PLUTO
knockdown.
(H) GSEA showed that genes that were down-
regulated upon knockdown of PDX1 and PLUTO
were enriched in genes whose enhancers were
bound by PDX1 (red) in islets but not in ten control gene sets (black) that were expressed at similar levels as PDX1-bound genes.
(I) Knockdown of PDX1 and PLUTO resulted in differential expression of genes with similar biological process annotations.
(J) Examples of known PDX1-regulated genes that are also co-regulated by PLUTO in parallel knockdown experiments. mRNA levels were assessed as in (B).
Error bars denote SEM; ***p < 103, **p < 0.01, *p < 0.05 (Student’s t test).previous findings by demonstrating a functional role of lncRNAs
in lineage-specific TF networks.
Our findings invite the question of what molecular mecha-
nisms underlie the regulatory effects of b cell lncRNAs. LncRNAs
have been proposed to control gene expression through diverse
molecular mechanisms, including the formation of protein-spe-
cific interactions and scaffolds, RNA-DNA or RNA-RNA hybrids,
the titration of miRNAs, and the modulation of 3D chromosomalstructures (Rinn and Chang, 2012; Wang and Chang, 2011),
whereas some transcripts currently defined as lncRNAs can
theoretically encode for atypical small peptide sequences
(Andrews and Rothnagel, 2014). Our knockdown and co-
expression analyses have identified a subset of functional
lncRNAs that appear to regulate a nearby gene, suggesting a
lncRNA-based cis-regulatory mechanism, whereas others are
likely to exert trans-regulatory effects. We focused on oneCell Metabolism 25, 400–411, February 7, 2017 407
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Figure 7. PLUTORegulatesPDX1 Transcrip-
tion and 3D Chromatin Structure
(A) The mRNA stability of PDX1 was unaffected by
PLUTO knockdown. PDX1mRNAwasmeasured in
control and PLUTO amiRNA knockdown in EndoC-
bH1 cells after Actinomycin D (ActD) treatment
(n = 3). mRNA levels are presented as a percentage
of levels observed at time = 0.
(B) Knockdown of PLUTO was carried out as in
Figure 6B, and this led to reduced PDX1 tran-
scription, as assessed by qPCR analysis of intronic
PDX1 RNA levels using hydrolysis probes. Values
were normalized to TBP mRNA and expressed as
fold over the control amiRNA sample (n = 4).
(C) Schematic of selected epigenomic features of
the PDX1 locus.
(D) PLUTO is required for 3D contacts between the
PDX1 promoter and distal enhancers. 3C analysis
revealed that knockdown of PLUTO resulted in
reduced contacts between the PDX1 promoter
(anchor) and two enhancers (E1 and E2). Interac-
tion signals were normalized to a control region on
the PDX1 intron. CTL represents a negative control
region that does not harbor interactions with the
PDX1 promoter. Error bars denote ± SEM, and
p values are from a Student’s t test.
(E) PLUTO knockdown resulted in impaired 3D
contacts between the PDX1 promoter and its
adjacent enhancer cluster, causing reduced PDX1
transcriptional activity.functional nuclear-enriched b cell lncRNA, PLUTO, and found
that its function in b cell networks is at least in part due to its
ability to elicit an effect on the transcription of its adjacent
gene, PDX1, which encodes a key b cell transcription factor.
Importantly, this was observed for both the mouse and human
orthologs, and similar effects were obtained through RNAi
suppression or through CRISPR-induced transcriptional interfer-
ence of PLUTO. Our studies further showed that PLUTO pro-
motes 3D interactions between the PDX1 promoter and its
upstream enhancer cluster, which is contained within the body
of the PLUTO gene. We thus propose that PLUTO regulates
the 3D architecture of the enhancer cluster at the PDX1 locus.
This finding is reminiscent but distinct from earlier examples of
non-coding RNA genes that modulate 3D chromosomal struc-
ture (Lai et al., 2013; Yao et al., 2010). Given that a significant
number of lncRNAs are co-expressed with adjacent lineage-
specific protein-coding genes, it is possible that the general
regulatory paradigm described here is relevant to analogous
lncRNA-protein coding gene pairs.
Taken together, our data implicate cell-specific lncRNAs in
human b cell transcriptional programs. Given the importance
of TFs in the pathophysiology of human diabetes and their
role in b cell programming strategies, it now seems reasonable
to explore whether b cell lncRNAs also play analogous roles408 Cell Metabolism 25, 400–411, February 7, 2017(Bell and Polonsky, 2001; Flanagan et al.,
2014; Zhou et al., 2008). The findings re-
ported here therefore strengthen earlier
suggestions that defects in b cell lncRNAs
might contribute to the pathogenesis of
human diabetes (Fadista et al., 2014;Mora´n et al., 2012) and warrant an assessment of whether they
can be harnessed to promote b cell differentiation, function, or
cellular mass.
EXPERIMENTAL PROCEDURES
Pancreatic Islets
Human islets used for RNA-seq and chromatin immunoprecipitation
sequencing (ChIP-seq) were cultured with CMRL 1066 medium containing
10% fetal calf serum (FCS) before shipment, after which they were cultured
for 3 days with RPMI 1640 medium containing 11 mM glucose and supple-
mented with 10% FCS.
Glucose-Stimulated Insulin Release
Glucose-stimulated insulin release was assayed in EndoC-bH1 or EndoC-bH3
cells as described previously (Benazra et al., 2015; Ravassard et al., 2011).
RNA Analysis
RNAwas isolated with Tripure (Roche) and treatedwith DNase I (Sigma). qPCR
was performed with SYBR green or Taqman probe detection (van Arensber-
gen et al., 2010). See Table S4 for oligonucleotide and probe sequences.
amiRNA and CRISPRi Experiments
Lentiviral vectors carrying amiRNAs targeting TFs, lncRNAs, and non-targeting
control sequences were transduced into the EndoC-bH1 human b cell line as
described previously (Castaing et al., 2005; Ravassard et al., 2011; Scharf-
mann et al., 2014).
Figure S1A illustrates the vector design. Oligonucleotide sequences are
shown in Table S4. Non-transduced cells were assayed in parallel. Cells
were harvested 80 hr post transduction for RNA extraction. For transduction
of human islets, islets were first dispersed using trypsin-EDTA and gentle
agitation. CRISPRi experiments were performed with two gRNAs designed
to target PLUTO exon 1 or two unrelated intergenic control regions and trans-
fected in EndoC-bH3 cells (Table S4).
Gene Expression Array Analysis
RNA was hybridized onto HTA2.0 Affymetrix arrays. RMA normalization
was carried out using Expression Console (Affymetrix). Gene-based
differential expression analysis was done using Transcriptome Analysis
Console (TAC, Affymetrix). Enhancer cluster genes were defined by
genes that were associated with clustered islet enhancers that show top
50 percentile binding by TFs (PDX1, FOXA2, NKX2-2, NKX6.1, and MAFB)
as defined previously (Pasquali et al., 2014). Pancreatic islet gene
sets used for enrichment analysis are shown in Table S5. A list of islet-
enriched genes was generated as those with more than two SDs higher
expression in human islets than the average expression in 16 human tissues
(Table S5).
Differential Expression in IGT and T2D Islets
RNA-seq data have been described previously (Fadista et al., 2014). The sam-
ples were aligned to the hg19 genome using STAR aligner version 2.3.0 as
described in the Supplemental Experimental Procedures, quantification was
carried out with HTseq-Count 0.6.1, and differential expression analysis of
lncRNA genes was done using DEseq2 1.10 (Table S3) using an adjusted
p value threshold of 0.05.
3C
3C and 4C-seq was carried out as described previously (Pasquali et al., 2014;
Tena et al., 2011) For real-time PCR quantification, readings were normalized
to a control region within the PDX1 intron. Normalized values are expressed as
a fraction of non-targeting amiRNA control sample. See Table S4 for oligonu-
cleotide sequences.
Annotation of Islet lncRNAs
LncRNAs were annotated through de novo assembly of 5 billion stranded
paired-end RNA-seq reads from 41 human islet samples, filtered for expres-
sion in FACS-purified b cell cells, lack of enrichment in the pancreatic exocrine
fraction to exclude acinar contaminants, and the presence of H3K4me3
enrichment in the vicinity of the 50 end. Amore detailed description of the anno-
tation process is provided in the Supplemental Information. Annotations are
available in Table S3 and can be accessed on a UCSC Genome Browser
(GRCh37/hg19) session by selecting ‘‘track hubs’’ and ‘‘Human Islet
lncRNAs.’’ Alternatively, the track hub can be directly visualized in the UCSC
Genome Browser using the following link: http://genome.ucsc.edu/cgi-bin/
hgTracks?db=hg19&hubUrl=http://www.imperial.ac.uk/medicine/beta-cell-
genome-regulation-laboratory/data/HILNCs/HILNCs.txt&hgS_loadUrlName=
http://www.imperial.ac.uk/medicine/beta-cell-genome-regulation-laboratory/
data/.
Network Analysis
The WGCNA(v2) tool was used to build a co-transcriptional network based on
mRNAs from 64 human islet RNA-seq samples.
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